Erika Fisher Lietzan

Publications

• Petition Power
  74 AM. U. L. REV. (2024) · American University Law Review · 2024
• The Case Of The Missing Device Patents, Or: Why Device Patents Matter
  33 FORDHAM INTELL. PROP. MEDIA & ENT. L.J. 409 (2023) · Fordham Intellectual Property, Media and Entertainment Law Journal · 2023
• Solutions Still Searching for a Problem: A Call for Relevant Data to Support “Evergreening” Allegations
  33 FORDHAM INTELL. PROP. MEDIA & ENT. L.J. 788 (2023) · Fordham Intellectual Property, Media and Entertainment Law Journal · 2023
• Distorted Drug Patents
  95 WASH. L. REV. 1317 (2020) · Washington Law Review · 2020
• Early Access to Unapproved Medicines in the United States and France
  19 YALE J. HEALTH POL'Y L. & ETHICS (2020) · Yale Journal of Health Policy, Law, and Ethics · 2020

• The Surprising Reach of FDA Regulation of Cannabis Even After Descheduling
  68 AM. U. L. REV. (2019) · American University Law Review · 2019
• The "Evergreening" Metaphor in Intellectual Property Scholarship
  53 AKRON L. REV. (2019) · Akron Law Review · 2019
• Access Before Evidence and the Price of The FDA’s New Drug Authorities
  53 U. RICH. L. REV. 1243 (2019) · University of Richmond Law Review · 2019
• The Drug Innovation Paradox
  83 MO. L. REV. (2018) · Missouri Law Review · 2018
• The History and Political Economy of the Hatch-Waxman Amendments
  49 SETON HALL L. REV. (2018) · Seton Hall Law Review · 2018
• The Uncharted Waters of Competition and Innovation in Biological Medicines
  44 FLA. ST. U. L. REV. 883 (2017) · Florida State University Law Review · 2017
• A New Framework for Assessing Clinical Data Transparency Initiatives
  18 MARQ. INTELL. PROP. L. REV. 33 (2014) · Marquette Intellectual Property Law Review · 2014
• Thoughts on Preemption in the Wake of the Levine Decision
  13 J. HEALTH CARE L. & POL'Y 225 (2010) · Journal of Health Care Law and Policy · 2010